Cargando…

PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC

Chemotherapy resistance is a major problem in non-small cell lung cancer (NSCLC) treatment. A major mechanism of chemoresistance involves stabilization of the NRF2 transcription factor. NRF2 levels are normally tightly regulated through interaction with KEAP1, an adaptor that targets NRF2 to the CUL...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Lili, Zhang, Rui, Chen, Jie, Xue, Qun, Moghal, Nadeem, Tsao, Ming-Sound
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712044/
https://www.ncbi.nlm.nih.gov/pubmed/31455821
http://dx.doi.org/10.1038/s41598-019-48763-4
_version_ 1783446610077810688
author Ji, Lili
Zhang, Rui
Chen, Jie
Xue, Qun
Moghal, Nadeem
Tsao, Ming-Sound
author_facet Ji, Lili
Zhang, Rui
Chen, Jie
Xue, Qun
Moghal, Nadeem
Tsao, Ming-Sound
author_sort Ji, Lili
collection PubMed
description Chemotherapy resistance is a major problem in non-small cell lung cancer (NSCLC) treatment. A major mechanism of chemoresistance involves stabilization of the NRF2 transcription factor. NRF2 levels are normally tightly regulated through interaction with KEAP1, an adaptor that targets NRF2 to the CUL3 E3 ubiquitin ligase for proteolysis. In NSCLC, aberrant NRF2 stabilization is best understood through mutations in NRF2, KEAP1, or CUL3 that disrupt their interaction. Biochemical studies, however, have revealed that NRF2 can also be stabilized through expression of KEAP1-interacting proteins that competitively sequester KEAP1 away from NRF2. Here, we have identified PIDD, as a novel KEAP1-interactor in NSCLC that regulates NRF2. We show that this interaction allows PIDD to reduce NRF2 ubiquitination and increase its stability. We also demonstrate that PIDD promotes chemoresistance in NSCLC cells both in vitro and in vivo, and that this effect is dependent on NRF2. Finally, we report that NRF2 protein expression in a NSCLC cohort exceeds the typical incidence of combined NRF2, KEAP1, and CUL3 mutations, and that NRF2 expression in this cohort is correlated with PIDD levels. Our data identify PIDD as a new NRF2 regulator, and suggest that variations in PIDD levels contribute to differential chemosensitivities among NSCLC patients.
format Online
Article
Text
id pubmed-6712044
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67120442019-09-13 PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC Ji, Lili Zhang, Rui Chen, Jie Xue, Qun Moghal, Nadeem Tsao, Ming-Sound Sci Rep Article Chemotherapy resistance is a major problem in non-small cell lung cancer (NSCLC) treatment. A major mechanism of chemoresistance involves stabilization of the NRF2 transcription factor. NRF2 levels are normally tightly regulated through interaction with KEAP1, an adaptor that targets NRF2 to the CUL3 E3 ubiquitin ligase for proteolysis. In NSCLC, aberrant NRF2 stabilization is best understood through mutations in NRF2, KEAP1, or CUL3 that disrupt their interaction. Biochemical studies, however, have revealed that NRF2 can also be stabilized through expression of KEAP1-interacting proteins that competitively sequester KEAP1 away from NRF2. Here, we have identified PIDD, as a novel KEAP1-interactor in NSCLC that regulates NRF2. We show that this interaction allows PIDD to reduce NRF2 ubiquitination and increase its stability. We also demonstrate that PIDD promotes chemoresistance in NSCLC cells both in vitro and in vivo, and that this effect is dependent on NRF2. Finally, we report that NRF2 protein expression in a NSCLC cohort exceeds the typical incidence of combined NRF2, KEAP1, and CUL3 mutations, and that NRF2 expression in this cohort is correlated with PIDD levels. Our data identify PIDD as a new NRF2 regulator, and suggest that variations in PIDD levels contribute to differential chemosensitivities among NSCLC patients. Nature Publishing Group UK 2019-08-27 /pmc/articles/PMC6712044/ /pubmed/31455821 http://dx.doi.org/10.1038/s41598-019-48763-4 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Ji, Lili
Zhang, Rui
Chen, Jie
Xue, Qun
Moghal, Nadeem
Tsao, Ming-Sound
PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC
title PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC
title_full PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC
title_fullStr PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC
title_full_unstemmed PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC
title_short PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC
title_sort pidd interaction with keap1 as a new mutation-independent mechanism to promote nrf2 stabilization and chemoresistance in nsclc
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712044/
https://www.ncbi.nlm.nih.gov/pubmed/31455821
http://dx.doi.org/10.1038/s41598-019-48763-4
work_keys_str_mv AT jilili piddinteractionwithkeap1asanewmutationindependentmechanismtopromotenrf2stabilizationandchemoresistanceinnsclc
AT zhangrui piddinteractionwithkeap1asanewmutationindependentmechanismtopromotenrf2stabilizationandchemoresistanceinnsclc
AT chenjie piddinteractionwithkeap1asanewmutationindependentmechanismtopromotenrf2stabilizationandchemoresistanceinnsclc
AT xuequn piddinteractionwithkeap1asanewmutationindependentmechanismtopromotenrf2stabilizationandchemoresistanceinnsclc
AT moghalnadeem piddinteractionwithkeap1asanewmutationindependentmechanismtopromotenrf2stabilizationandchemoresistanceinnsclc
AT tsaomingsound piddinteractionwithkeap1asanewmutationindependentmechanismtopromotenrf2stabilizationandchemoresistanceinnsclc